2024
Persistent and multiclonal malaria parasite dynamics despite extended artemether-lumefantrine treatment in children
Goodwin J, Kajubi R, Wang K, Li F, Wade M, Orukan F, Huang L, Whalen M, Aweeka F, Mwebaza N, Parikh S. Persistent and multiclonal malaria parasite dynamics despite extended artemether-lumefantrine treatment in children. Nature Communications 2024, 15: 3817. PMID: 38714692, PMCID: PMC11076639, DOI: 10.1038/s41467-024-48210-7.Peer-Reviewed Original ResearchConceptsDay 7 lumefantrine concentrationsArtemether-lumefantrine treatmentRing-stage parasitesEarly post-treatmentEarly post-treatment periodArtemether-lumefantrineArtemisinin resistanceDay regimenMulticlonal infectionsEfficacious therapyFollow-upRandomized trialsPersistent clonesTransmission settingsEffective treatmentPost-treatment periodRegimensAntimalarial studiesStandard diagnosticsStandard 3DaysPost-treatmentChildrenTreatmentTherapy
2022
Impact of Drug Exposure on Resistance Selection Following Artemether‐Lumefantrine Treatment for Malaria in Children With and Without HIV in Uganda
Kay K, Goodwin J, Ehrlich H, Ou J, Freeman T, Wang K, Li F, Wade M, French J, Huang L, Aweeka F, Mwebaza N, Kajubi R, Riggs M, Ruiz‐Garcia A, Parikh S. Impact of Drug Exposure on Resistance Selection Following Artemether‐Lumefantrine Treatment for Malaria in Children With and Without HIV in Uganda. Clinical Pharmacology & Therapeutics 2022, 113: 660-669. PMID: 36260349, PMCID: PMC9981240, DOI: 10.1002/cpt.2768.Peer-Reviewed Original ResearchConceptsLopinavir-ritonavirLumefantrine concentrationsSensitive parasitesRecurrence riskPopulation PK/PD modelArtemether-lumefantrine treatmentTrimethoprim-sulfamethoxazole prophylaxisPK/PD modelPopulation PK modelFirst-order absorptionHigh transmission regionsAntiretroviral regimensLumefantrine exposureLumefantrine susceptibilityPfcrt K76Pfmdr1 N86Suboptimal dosingArtemether-lumefantrineTwo-compartment modelHIV statusRecurrent infectionsCombination therapyDrug exposurePrimary treatmentArtemisinin resistanceClinical characteristics of Plasmodium falciparum infection among symptomatic patients presenting to a major urban military hospital in Cameroon
Hodson DZ, Mbarga Etoundi Y, Mbatou Nghokeng N, Mohamadou Poulibe R, Magne Djoko S, Goodwin J, Cheteug Nguesta G, Nganso T, Armstrong JN, Andrews JJ, Zhang E, Wade M, Eboumbou Moukoko CE, Boum Y, Parikh S. Clinical characteristics of Plasmodium falciparum infection among symptomatic patients presenting to a major urban military hospital in Cameroon. Malaria Journal 2022, 21: 298. PMID: 36273147, PMCID: PMC9588226, DOI: 10.1186/s12936-022-04315-2.Peer-Reviewed Original ResearchConceptsP. falciparum infectionPopulation attributable risk percentFalciparum infectionPlasmodium falciparum infectionYears of ageClinical characteristicsUrban hospitalMilitary HospitalAttributable risk percentHigher positivity rateLikelihood ratioRapid diagnostic testsMajor urban hospitalRural African settingConclusionsThe prevalenceHigh feverSymptomatic patientsHemoglobin levelsAnemia prevalenceSevere anemiaEmergency departmentVenous samplesClinical surveyPositivity rateWHO definitionComparison of the Respiratory Resistomes and Microbiota in Children Receiving Short versus Standard Course Treatment for Community-Acquired Pneumonia
Pettigrew MM, Kwon J, Gent JF, Kong Y, Wade M, Williams DJ, Creech CB, Evans S, Pan Q, Walter EB, Martin JM, Gerber JS, Newland JG, Hofto ME, Staat MA, Fowler VG, Chambers HF, Huskins WC. Comparison of the Respiratory Resistomes and Microbiota in Children Receiving Short versus Standard Course Treatment for Community-Acquired Pneumonia. MBio 2022, 13: e00195-22. PMID: 35323040, PMCID: PMC9040816, DOI: 10.1128/mbio.00195-22.Peer-Reviewed Original ResearchConceptsCommunity-acquired pneumoniaShort-course strategyBeta-lactam therapyTreatment strategiesAntibiotic useRespiratory microbiomePediatric community-acquired pneumoniaDays of antibioticsShorter antibiotic coursesStandard-strategy groupDays of therapyStandard treatment strategyAntibiotic resistanceAdditional rationaleEffectiveness of interventionsImpact of durationAntibiotic coursesThroat swabsCourse strategyAntibiotic treatmentPediatric pneumoniaCourse treatmentLow prevalencePneumoniaAntibiotic resistance determinants
2019
Comparison on simultaneous capillary and venous parasite density and genotyping results from children and adults with uncomplicated malaria: a prospective observational study in Uganda
Lehane A, Were M, Wade M, Hamadu M, Cahill M, Kiconco S, Kajubi R, Aweeka F, Mwebaza N, Li F, Parikh S. Comparison on simultaneous capillary and venous parasite density and genotyping results from children and adults with uncomplicated malaria: a prospective observational study in Uganda. BMC Infectious Diseases 2019, 19: 559. PMID: 31242863, PMCID: PMC6595677, DOI: 10.1186/s12879-019-4174-1.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAIDS-Related Opportunistic InfectionsAnimalsAntimalarialsArtemether, Lumefantrine Drug CombinationCapillariesChildChild, PreschoolDrug MonitoringFemaleGenotypeGenotyping TechniquesHIVHIV InfectionsHumansInfantMalaria, FalciparumMaleMiddle AgedParasite LoadParasitemiaPlasmodium falciparumUgandaVeinsYoung AdultConceptsTime of presentationVenous blood smearsProspective observational studyParasite densityVenous compartmentBlood smearsVenous samplesObservational studyMSP-2Uncomplicated Plasmodium falciparum malariaTrial registrationThe trialPlasmodium falciparum malariaResultsTwo hundred twentyMalaria parasite densityClinical research settingResearch settingsUncomplicated malariaArtemether-lumefantrineFalciparum malariaParasite genotypingBland-Altman analysisHundred twentyMalaria diagnosisNew infectionsGold standard methodEfficacy and risk of harms of repeat ivermectin mass drug administrations for control of malaria (RIMDAMAL): a cluster-randomised trial
Foy BD, Alout H, Seaman JA, Rao S, Magalhaes T, Wade M, Parikh S, Soma DD, Sagna AB, Fournet F, Slater HC, Bougma R, Drabo F, Diabaté A, Coulidiaty AGV, Rouamba N, Dabiré RK. Efficacy and risk of harms of repeat ivermectin mass drug administrations for control of malaria (RIMDAMAL): a cluster-randomised trial. The Lancet 2019, 393: 1517-1526. PMID: 30878222, PMCID: PMC6459982, DOI: 10.1016/s0140-6736(18)32321-3.Peer-Reviewed Original ResearchConceptsMass drug administrationCluster-randomised trialIntervention groupMalaria episodesControl groupDrug AdministrationDetection cohortMass administrationIvermectin mass drug administrationUncomplicated malaria episodesClinical malaria episodesMalaria transmission seasonSingle oral dosesControl of malariaAdverse eventsCumulative incidencePrimary outcomeOral dosesEligible participantsAdverse reactionsFurther dosesTwo-armExclusion criteriaTransmission seasonTreatment phase
2016
Association of sputum microbiota profiles with severity of community-acquired pneumonia in children
Pettigrew MM, Gent JF, Kong Y, Wade M, Gansebom S, Bramley AM, Jain S, Arnold SL, McCullers JA. Association of sputum microbiota profiles with severity of community-acquired pneumonia in children. BMC Infectious Diseases 2016, 16: 317. PMID: 27391033, PMCID: PMC4939047, DOI: 10.1186/s12879-016-1670-4.Peer-Reviewed Original ResearchConceptsCommunity-acquired pneumoniaCAP severityMicrobiota profilesClinical courseRespiratory microbiotaPediatric community-acquired pneumoniaIntensive care unit admissionNasopharyngeal/oropharyngeal samplesCare unit admissionOdds of lengthInduced sputum samplesRespiratory tract microbiotaOP samplesRibosomal RNA sequencingUnit admissionDecreased oddsSputum samplesChildren 6Oropharyngeal samplesMicrobiota influenceChildren 5Logistic regressionSputumSeverityPneumonia